



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/899,575	07/05/2001	Jan Zur Megede	PP01631.102 (CHIR-1631/03)	1709
7590 01/24/2007 Anne S. Dollard CHIRON CORPORATION Intellectual Property - R440 P.O. Box 8097 Emeryville, CA 94662-8097			EXAMINER PARKIN, JEFFREY S	
			ART UNIT	PAPER NUMBER
			1648	

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	01/24/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No. 09/899,575		Applicant(s) MEGEDE ET AL.	
Examiner Jeffrey S. Parkin, Ph.D.		Art Unit 1648	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 03 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 26 October 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 2-4, 38 and 78-96 is/are pending in the application.
- 4a) Of the above claim(s) 2-4 and 78-96 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ ~~Claim(s) 38 is/are rejected.~~
- 7) ☒ Claim(s) 38 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input checked="" type="checkbox"/> Other: <u>Notice to Comply...</u> |

Serial No.: 09/899,575
Applicants: Zur Megede, J., et al.

Docket No.: PP01631.102
Filing Date: 07/05/01

Detailed Office Action

Status of the Claims

Claims 2-4, 38, and 78-96 are pending in the instant application. Claims 2-4 and 78-96 stand withdrawn from further consideration by the examiner, pursuant to 37 C.F.R. § 1.142(b), as being drawn to a non-elected invention. Applicants again traverse the restriction requirement and submit that it would not constitute an undue burden if all sequences were searched concomitantly. The basis for the restriction requirement and the propriety of the requirement were adequately address in the last office action mailed 04 April, 2006.

37 C.F.R. § 1.98

Applicants are reminded that the information disclosure statement filed 30 June, 2005, was placed in the application file and the information referred to therein was considered. However, as previously set forth, applicants are reminded that the information disclosure statement filed 09 June, 2003, failed to comply with the provisions of 37 C.F.R. § 1.97, 1.98 and M.P.E.P. § 609. The IDS listed 64 patent documents, 128 foreign patent documents, and 154 non-patent literature documents. Because the excessive number of references would constitute an undue burden on the examiner, they have not been considered since a statement identifying their relevance to the claimed invention has not been provided. Accordingly, the IDS was placed in the application file, but the information referred to therein was not considered as to the merits. Applicants noted that these references were previously supplied in U.S. Serial No. 09/610,313. However, perusal of this application failed to identify the various documents cited or a description identifying their relevance.

37 C.F.R. § 1.821-1.825

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. § 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicants are reminded that sequences appearing in the **specification** (e.g., see page 107) and/or **drawings** (e.g., see Figure 105) must be identified by a sequence identifier (SEQ ID NO.:) in accordance with 37 C.F.R. § 1.821(d). Sequence identifiers for sequences appearing in the drawings may appear in the Brief Description of the Drawings. Applicant must provide appropriate amendments to the specification and/or drawings inserting the required sequence identifiers. Extensive amendments may necessitate the submission of a substitute specification.

Claim Objections

Claim 38 is objected to because of the following informalities: the claim references non-elected nucleotide sequences. Applicants are reminded of the original restriction requirement set forth in the office action mailed 05 January, 2005, and the petition decided and mailed 28 January, 2006. The claim language should be amended to reflect the election. Appropriate correction is required.

37 C.F.R. § 1.57(d)

The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code (e.g., see pages 36 and 50). Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See

M.P.E.P. § 608.01.

35 U.S.C. § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The previous rejection of claim 38 under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, is hereby withdrawn in response to applicants' arguments.

Allowable Subject Matter

SEQ ID NO.: 120 appears to be free of the prior art and would be allowable with appropriate claim amendments (i.e., An expression cassette comprising a polynucleotide encoding a modified immunogenic human immunodeficiency virus type 1 (HIV-1) Env glycoprotein wherein said polynucleotide comprises SEQ ID NO.: 120). Applicants are invited to contact the examiner to discuss suggested revisions to the claim language.

Correspondence


Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, James C. Housel, can be reached at (571) 272-0902. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may

be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Trademark Office (Office) requires most patent related correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. For further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,



Jeffrey S. Parkin, Ph.D.
Primary Examiner
Art Unit 1648

21 January, 2007

Notice to Comply	Application No. 09/899,575	Applicant(s) Zur Megede, J., <i>et al.</i>	
	Examiner Jeffrey S. Parkin	Art Unit 1648	Paper No. 01/27/2007

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: applicants are reminded that Sequences appearing in the **specification** and/or **drawings** must be identified by a sequence identifier (SEQ ID NO.:) in accordance with 37 C.F.R. § 1.821(d). Sequence identifiers for sequences appearing in the drawings may appear in the Brief Description of the Drawings. Applicant must provide appropriate amendments to the specification and/or drawings inserting the required sequence identifiers. Extensive amendments may necessitate the submission of a substitute specification.

Applicant May Need to Provide:

- ☒ An substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov.

To Download Patentin Software, visit <http://www.uspto.gov/web/patents/software.htm>.

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Synthetic HIV Type C expression cassettes provides dramatic increases in production of their protein products, relative to the native (wild-type Subtype C) sequences, when expressed in a variety of cell lines.

5 **B. Signal Peptide Leader Sequences**

The ability of various leader sequences to drive expression was tested by transfecting cells with wild type or synthetic Env-encoding expression cassettes operably linked to different leader sequences and evaluating expression of Env polypeptide by ELISA or Western Blot. The amino acid and nucleotide sequence of various signal
10 peptide leader sequences are shown in Table 4.

Table 4

Leader	Amino acid sequence	DNA sequence
15 WTnative (8_2_TV 1_C.ZA)	MRVMGTQKNCQQWWIWGI LGFWMLMIC	ATGAGAGTGATGGGGACACAGA AGAATTGTCAACAATGGTGGATA TGGGGCATCTTAGGCTTCTGGAT GCTAATGATTTGT
WTmod (8_2_TV 1_C.ZA)	MRVMGTQKNCQQWWIWGI LGFWMLMIC	ATGCGCGTGATGGGCACCCAGAA GAACTGCCAGCAGTGGTGGATCT GGGGCATCCTGGGCTTCTGGATG CTGATGATCTGC
20 Tpa1	MDAMKRGLCCVLLCGAVFVSPS AS	ATGGATGCAATGAAGAGAGGGC TCTGCTGTGTGCTGCTGCTGTGTG GAGCAGTCTTCGTTTCGCCCAGC GCCAGC
Tpa2	MDAMKRGLCCVLLCGAVFVSPS	ATGGATGCAATGAAGAGAGGGC TCTGCTGTGTGCTGCTGCTGTGTG GAGCAGTCTTCGTTTCGCCCAGC

293 cells were transiently transfected using standard methods with native and sequence-modified constructs encoding the gp120 and gp140 forms of the
25 8_2_TV1_C.ZA (TV1c8.2) envelope. Env protein was measure in cell lysates and supernatants using an in-house Env capture ELISA. Results are shown in Table 5 below and indicate that the wild-type signal peptide leader sequence of the TV1c8.2 can be used

↓: is the regions for β -sheet deletions

*: is the N-linked glycosylation sites for subtype C TV1 and TV2. Possible mutation (N → Q) or deletions can be performed.

		1	50
SF162	(1)	----MDAMKRGLCCLLLCGAVFVSPSAVEKEWVTVYVGPVWKEATTL	
TV1.8_2	(1)	MRVMGTQKNCCQWWIWGILGFWMLMICNTEDLWVTVYVGPVWRDAKTL	
TV1.8_5	(1)	MRVMGTQKNCCQWWIWGILGFWMLMICNTEDLWVTVYVGPVWRDAKTL	
TV2.12-5/1	(1)	MRARGILKNYRHHWIIWGILGFWMLMICNVKGLWTVYVGPVVGREAKTTL	
Consensus	(1)	MRVMGTQKNCCQWWIWGILGFWMLMICNVEDLWVTVYVGPVWRDAKTL	
		51	100
SF162	(47)	FCASDAKAYETEVHNVWATHACVPTDPNPQEVILENVTENFMWKNNMVD	
TV1.8_2	(51)	FCASDAKAYETEVHNVWATHACVPTDPNPQEVILENVTENFMWKNNMVD	
TV1.8_5	(51)	FCASDAKAYETEVHNVWATHACVPTDPNPQEVILENVTENFMWKNNMVD	
TV2.12-5/1	(51)	FCASDAKAYETEVHNVWATHACVPTDPNPQEVILENVTENFMWKNNMVD	
Consensus	(51)	FCASDAKAYETEVHNVWATHACVPTDPNPQEVILENVTENFMWKNNMVD	
		101	150
		$\beta 2/V1V2/\beta 3$	
SF162	(97)	QMHEDIISLWDQSLKPCVKLTPLCVTLNCTNNTVTGNRTVTGNSNTNNG	
TV1.8_2	(101)	QMHEDIISLWDQSLKPCVKLTPLCVTLNCTNNTVTGNRTVTGNSNTNNG	
TV1.8_5	(101)	QMHEDIISLWDQSLKPCVKLTPLCVTLNCTNNTVTGNRTVTGNSNTNNG	
TV2.12-5/1	(101)	QMHEDIISLWDQSLKPCVKLTPLCVTLNCTNNTVTGNRTVTGNSNTNNG	
Consensus	(101)	QMHEDIISLWDQSLKPCVKLTPLCVTLNCTNNTVTGNRTVTGNSNTNNG	
		151	200
SF162	(139)	WKEMDRGEIKNCSEKVTSTIENKMOKEYALFYKLDVPLNN--DNTSY	
TV1.8_2	(151)	TGIYNIEEMKNCSEFNATIELRDKKHKEYALFYKLDVPLNN--ENSDNFTY	
TV1.8_5	(151)	NATYKYEEMKNCSEFNATIELRDKKHKEYALFYKLDVPLNN--ENSDNFTY	
TV2.12-5/1	(141)	-----KOMKNCSEYVITIELRDKKHKEYALFYKLDVPLNN--ENSDNFTY	
Consensus	(151)	A Y EEMKNCSEFNATIELRDKKHKEYALFYKLDVPLNN--ENSDNFTY	
		201	250
SF162	(185)	RLINCNSTSTITQACPKVSFDPPIPIHYCAPAGYAILKCNKKTNGTGPCYN	
TV1.8_2	(199)	RLINCNSTSTITQACPKVSFDPPIPIHYCAPAGYAILKCNKKTNGTGPCYN	
TV1.8_5	(199)	RLINCNSTSTITQACPKVSFDPPIPIHYCAPAGYAILKCNKKTNGTGPCYN	
TV2.12-5/1	(185)	RLINCNSTSTITQACPKVSFDPPIPIHYCAPAGYAILKCNKKTNGTGPCYN	
Consensus	(201)	RLINCNSTSTITQACPKVSFDPPIPIHYCAPAGYAILKCNKKTNGTGPCYN	
		251	300
SF162	(235)	VSTVQCTHGIRKPVSTQLLNGLSLAEEGIIIRSENLTENTKTIIIVHLNES	
TV1.8_2	(249)	VSTVQCTHGIRKPVSTQLLNGLSLAEEGIIIRSENLTENTKTIIIVHLNES	
TV1.8_5	(249)	VSTVQCTHGIRKPVSTQLLNGLSLAEEGIIIRSENLTENTKTIIIVHLNES	
TV2.12-5/1	(235)	VSTVQCTHGIRKPVSTQLLNGLSLAEEGIIIRSENLTENTKTIIIVHLNES	
Consensus	(251)	VSTVQCTHGIRKPVSTQLLNGLSLAEEGIIIRSENLTENTKTIIIVHLNES	
		301*	350
SF162	(285)	VEINCTRPNNNTRKSVRIGPGQAFYATNDIIGNIROAHCNISTDRWNKTL	
TV1.8_2	(299)	VEINCTRPNNNTRKSVRIGPGQAFYATNDIIGNIROAHCNISTDRWNKTL	
TV1.8_5	(299)	VEINCTRPNNNTRKSVRIGPGQAFYATNDIIGNIROAHCNISTDRWNKTL	
TV2.12-5/1	(285)	VEINCTRPNNNTRKSVRIGPGQAFYATNDIIGNIROAHCNISTDRWNKTL	
Consensus	(301)	VEINCTRPNNNTRKSVRIGPGQAFYATNDIIGNIROAHCNISTDRWNKTL	

FIGURE 105A

Figure 103 (SEQ ID NO:134) depicts the nucleotide sequence of a synthetic Nef-encoding polynucleotide derived from 12-5_1_TV2_C.ZA. The sequence includes a mutation at position 125 which results in a non-functional gene product.

5 Figure 104 (SEQ ID NO:135) depicts the nucleotide sequence of a synthetic Nef-encoding polynucleotide derived from 12-5_1_TV2_C.ZA. The synthetic polynucleotide includes a mutation that eliminates the myristoylation site of the Nef gene product.

Figure 105 depicts an alignment of Env polypeptides from various HIV isolates. The regions between the arrows indicate regions (of TV1 and TV2 clones) in the beta and/or bridging sheet region(s) that can be deleted and/or truncated. The "*" denotes N-linked glycosylation sites (of TV1 and TV2 clones), one or more of which can be
10 modified (e.g., deleted and/or mutated).

DETAILED DESCRIPTION OF THE INVENTION

The practice of the present invention will employ, unless otherwise indicated,
15 conventional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., *Remington's Pharmaceutical Sciences*, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990); *Methods In Enzymology* (S. Colowick and N. Kaplan, eds., Academic Press, Inc.); and *Handbook of Experimental Immunology*,
20 Vols. I-IV (D.M. Weir and C.C. Blackwell, eds., 1986, Blackwell Scientific Publications); Sambrook, et al., *Molecular Cloning: A Laboratory Manual* (2nd Edition, 1989); *Short Protocols in Molecular Biology*, 4th ed. (Ausubel et al. eds., 1999, John Wiley & Sons); *Molecular Biology Techniques: An Intensive Laboratory Course*, (Ream et al., eds., 1998, Academic Press); *PCR (Introduction to Biotechniques Series)*, 2nd ed.
25 (Newton & Graham eds., 1997, Springer Verlag).

All publications, patents and patent applications cited herein, whether *supra* or *infra*, are hereby incorporated by reference in their entirety.